Company Filing History:
Years Active: 2009-2012
Title: Catherine Germeau: Innovator in Cancer Research
Introduction
Catherine Germeau is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of cancer research, particularly through her innovative work on antigenic peptides.
Latest Patents
Catherine Germeau holds two patents, with her latest invention focusing on MAGE-C2 antigenic peptides and their uses. This invention involves isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2, and expression vectors that comprise these nucleic acid molecules. Additionally, it includes host cells that are transformed or transfected with the nucleic acid molecules or expression vectors. The invention also covers tetramers that consist of the peptides, HLA molecules, beta-microglobulin, and binding partners. Furthermore, it relates to methods for utilizing these peptides, nucleic acid molecules, expression vectors, and complexes, as well as cytolytic T cells that recognize the peptides in complex with an HLA molecule.
Career Highlights
Catherine Germeau is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues to advance her research and innovations in cancer treatment. Her work has been instrumental in developing new therapeutic approaches that leverage the immune system to target cancer cells.
Collaborations
Catherine collaborates with notable colleagues such as Wenbin Ma and Benoit Van Den Eynde, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Catherine Germeau's contributions to cancer research through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in cancer therapies.